Clinical Trial Update: Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 clinical trial evaluating the combination of bortezomib, daunorubicin, and cytarabine in older patients with previously untre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Inv
• Erythroid Leukemia
• Megakaryoblastic Leukemia
• Monocytic Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-02-05